Exemplos de uso de Randomisation was stratified em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
In ECHO, randomisation was stratified by screening viral load.
RAISE: 197 ITP patients were randomised 2:1, eltrombopag(n=135) to placebo(n=62), and randomisation was stratified based upon splenectomy status, use of ITP medicinal products at baseline and baseline platelet count.
Randomisation was stratified by Sokal risk score at the time of diagnosis.
In THRIVE, randomisation was stratified by screening viral load and by N(t)RTI BR.
Randomisation was stratified by HCV genotype 1, 2, 3, 4, 5, 6 and indeterminate.
Stratification: Randomisation was stratified by the intended use of ENF in the BR, previous use of darunavir and screening viral load.
Randomisation was stratified by screening HIV-1 RNA level≤ 100,000 copies/mL or.
Randomisation was stratified by geographic region, gender, prior maintenance, and ECOG PS.
Randomisation was stratified by tumour PD-L1 status and M stage M0/M1a/M1b versus M1c.
Randomisation was stratified by the presence or absence of cirrhosis and HCV genotype 1a versus 1b.
Randomisation was stratified by screening plasma viral load and screening CD4+ cell count.
Randomisation was stratified by screening HIV-1 RNA level< 100,000 copies/ml and> 100,000 copies/ml.
Randomisation was stratified by HCV genotype(1, 2, 4, 6, and indeterminate) and the presence or absence of cirrhosis.
Randomisation was stratified by BRAF and tumour PD-L1 status and best response to prior ipilimumab.
Randomisation was stratified by use of tenofovir disoproxil fumarate and/or lopinavir/ritonavir in the baseline regimen.
Randomisation was stratified by prior trastuzumab treatment and number of prior treatments for metastatic disease.
Randomisation was stratified by sites of disease and by time from discontinuation of prior adjuvant anti-oestrogen therapy.
Randomisation was stratified by documented sensitivity to prior hormonal therapy and by the presence of visceral metastasis.
Randomisation was stratified by breast cancer type(operable, locally advanced, or inflammatory) and ER and/or PgR positivity.
Randomisation was stratified by the presence or absence of cirrhosis and prior treatment experience treatment-naïve versus treatment-experienced.
Randomisation was stratified by geographic region, time to progression from the start of first-line therapy(< 6 months versus≥6 months) and disease measurability.
Randomisation was stratified by the presence or absence of cirrhosis, HCV genotype(1a versus 1b) and response to prior HCV therapy relapse/breakthrough versus non-response.
Randomisation was stratified by PD-L1 expression(≥5% vs.< 5% tumour cell membrane expression), BRAF status, and M stage per the American Joint Committee on Cancer(AJCC) staging system.
Randomisation was stratified by geographic region(Europe, North America, and Other), prior VEGF/VEGFR-targeted therapy(patients may have received 0 or 1 prior VEGF/VEGFR-targeted therapy), and age≤65 years or> 65 years.
Randomisation was stratified by PDGFR-α expression(positive versus negative), number of previous lines of treatment(0 versus 1 or more lines), histological tumour type(leiomyosarcoma, synovial sarcoma, and others) and ECOG performance status 0 or 1 versus 2.
Patients were stratified at randomisation by age( 75 vs.> 75 years) and stage ISS; Stages I and II vs. stage III.